DAPANORM TRIO 10

About

Dapanorm Trio is a sophisticated combination medication designed for the comprehensive management of type 2 diabetes mellitus, typically integrating Dapagliflozin (an SGLT2 inhibitor), Metformin (a biguanide), and a third antidiabetic agent, such as a DPP-4 inhibitor or sulfonylurea. This triple therapy targets multiple distinct physiological pathways involved in glucose regulation, offering a synergistic and robust approach to glycemic control. Dapagliflozin enhances glucose excretion via the kidneys, Metformin primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, while the third agent further optimizes insulin secretion or action depending on its class. This multi-pronged strategy helps achieve superior and sustained glycemic control, often accompanied by the added cardiovascular and renal protective benefits associated with dapagliflozin, making it a powerful and convenient therapeutic option for patients requiring intensive diabetes management to reach their treatment goals.

Uses

• Comprehensive management of type 2 diabetes mellitus.
• When dual therapy with Metformin and another agent is insufficient.
• To improve glycemic control in adults.
• As an adjunct to diet and exercise.

Directions For Use

Take orally as directed by your physician, usually with meals to minimize gastrointestinal side effects.

Benefits

• Potent reduction in blood glucose and HbA1c.
• Addresses multiple diabetes pathways.
• May promote weight loss (due to Dapagliflozin).
• Offers cardiovascular and renal protection.
• Improves insulin sensitivity.
• Convenient triple therapy in one pill.

Side Effects

• Genital yeast infections
• Urinary tract infections (UTIs)
• Diarrhea
• Nausea
• Abdominal pain
• Lactic acidosis (rare, Metformin-related)
• Hypoglycemia (especially with sulfonylurea component)
• Increased urination
• Dizziness
• Ketoacidosis (rare, Dapagliflozin-related)
• Vitamin B12 deficiency (Metformin-related)
• Metallic taste

Safety Measures

• Alcohol - Avoid excessive alcohol due to increased risk of lactic acidosis (Metformin) and hypoglycemia.
• Pregnancy - Not recommended during the second and third trimesters; consult a specialist.
• Breastfeeding - Not recommended due to potential for serious adverse effects in the infant and unknown excretion into breast milk.
• Liver - Use with caution in hepatic impairment; Metformin is contraindicated in severe liver disease.
• Kidney - Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73 m²); monitor kidney function closely.
• Lung - No specific contraindications or precautions related to lung conditions, but severe respiratory failure can increase lactic acidosis risk.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.